{"id":"W2947823476","doi":"10.1200/jco.2019.37.15_suppl.4079","title":"Pembrolizumab (pembro) for advanced biliary adenocarcinoma: Results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":132,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Biliary tract cancer; Clinical endpoint; Oncology; Gastroenterology; Clinical trial; Cancer; Immunotherapy; Gemcitabine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004660741,0.0006426506,0.0009015138,0.0004969129,0.0001806866,0.0007840228,0.0005723316,0.0006820399,0.002500989],"category_scores_gemma":[0.002136173,0.000282533,0.001237257,0.0007288033,0.0002543874,0.000654361,0.0005770827,0.0009857519,0.0006520937],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008070802,"about_ca_system_score_gemma":0.0009993998,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001366725,"about_ca_topic_score_gemma":0.004647602,"domain_scores_codex":[0.9991666,0.0003650384,0.0000953544,0.0001028244,0.0001473811,0.0001227539],"domain_scores_gemma":[0.99813,0.0003768519,0.0006754634,0.0001132865,0.0002228579,0.0004815241],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4321411,0.009444604,0.1045725,0.006575572,0.01138243,0.000616102,0.0005799295,0.002837609,0.03051419,0.0005870538,0.03046659,0.3702824],"study_design_scores_gemma":[0.2223282,0.2283863,0.4470915,0.001642562,0.01534394,0.002152775,0.0004318859,0.001515017,0.006719906,0.0006660364,0.07358056,0.0001412646],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9407672,0.03898567,0.0005221957,0.001399303,0.0001361,0.00166751,0.01021195,0.00008123876,0.006228756],"genre_scores_gemma":[0.9499118,0.01898156,0.001462772,0.001791707,0.0001953726,0.0009602215,0.02446014,0.00003577601,0.002200658],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004660741,"threshold_uncertainty_score":0.02464867,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1614750808309898,"score_gpt":0.4601049431994882,"score_spread":0.2986298623684984,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}